{"protocolSection": {"identificationModule": {"nctId": "NCT00392288", "orgStudyIdInfo": {"id": "EFC6695"}, "secondaryIdInfos": [{"id": "XRP1526"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.", "officialTitle": "A Multicenter, Multi-national, Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler (MDI) at 80 \u03bcg BID or 40 \u03bcg BID for 12 Weeks in Patients Aged 4 to <12 Years With Persistent Asthma."}, "statusModule": {"statusVerifiedDate": "2016-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-09"}, "primaryCompletionDateStruct": {"date": "2008-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-10-24", "studyFirstSubmitQcDate": "2006-10-24", "studyFirstPostDateStruct": {"date": "2006-10-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-07-01", "resultsFirstSubmitQcDate": "2009-11-27", "resultsFirstPostDateStruct": {"date": "2009-12-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-12-02", "lastUpdatePostDateStruct": {"date": "2017-02-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 \u03bcg twice daily (BID) or 40 \u03bcg BID for 12 weeks in patients with persistent asthma.\n\nSecondary objective: To assess the safety and tolerability of ciclesonide."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Bronchial Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 528, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo MDI", "type": "PLACEBO_COMPARATOR", "description": "double-blind", "interventionNames": ["Drug: Placebo"]}, {"label": "Ciclesonide MDI 40 \u00b5g BID", "type": "EXPERIMENTAL", "description": "double-blind", "interventionNames": ["Drug: Ciclesonide"]}, {"label": "Ciclesonide MDI 80 \u00b5g BID", "type": "EXPERIMENTAL", "description": "double-blind", "interventionNames": ["Drug: Ciclesonide"]}], "interventions": [{"type": "DRUG", "name": "Ciclesonide", "description": "Ciclesonide MDI 40 \u00b5g BID over twelve weeks", "armGroupLabels": ["Ciclesonide MDI 40 \u00b5g BID"]}, {"type": "DRUG", "name": "Ciclesonide", "description": "Ciclesonide MDI 80 \u00b5g BID over twelve weeks", "armGroupLabels": ["Ciclesonide MDI 80 \u00b5g BID"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo MDI over twelve weeks", "armGroupLabels": ["Placebo MDI"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12.", "description": "Change in FEV1 (Percent of predicted) from baseline to week 12. FEV1 was measured only in children between 6 to \\<12 years only. Least Squares Mean were adjusted for Baseline FEV1, age \\[yrs\\], pooled center, previous corticosteroid therapy and holding chamber.", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Total Daily Asthma Symptom Score at Week 12.", "description": "Change in total daily asthma symptom score from baseline to week 12. 5-Point, ordinal scale specifying patient's experience of symptoms during day and night from 0 (no symptoms) to 4 (symptoms that prevent the patient from engaging in daily activities or sleep)", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Use of Albuterol/Salbutamol at Week 12.", "description": "Change in albuterol/salbutamol use from baseline to week 12", "timeFrame": "Baseline and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* History of persistent bronchial asthma for at least 3 months prior to screening;\n* For patients with persistent bronchial asthma and being treated with a controller therapy: Documented use of an inhaled steroid or Singulair\u00ae 5mg once daily;\n* For patients with persistent bronchial asthma and not being treated with controller therapy: Patients may have documented use of a reliever therapy such as albuterol/salbutamol or may be untreated;\n* Morning Peak Expiratory Flow (AM PEF) of \u226490% of predicted values from the in-clinic spirometry after a 6 hour withhold of albuterol/salbutamol;\n* Only patients aged between 6 to \\<12 years must have a forced expiratory volume in one second (FEV1) of \u226550% to \u226485% of predicted normal after a 6 hour withhold of albuterol/salbutamol\n\nExclusion Criteria:\n\n* Nocturnal awakenings for asthma which require treatment with albuterol/salbutamol for 4 or more nights out of the last 7 days of the screening period;\n* Use of more than 8 puffs/day of albuterol/salbutamol on 3 or more consecutive days within the last 7\n* Upper or lower respiratory tract infection within 4 weeks prior to screening and during screening period;\n* History of life-threatening asthma, including a history of significant hypercarbia (pCO2 \\>45 mmHg), prior intubation, respiratory arrest, or seizures as a result of an exacerbation of asthma;\n* More than 3 in-patient hospitalization or emergency care visits due to asthma exacerbations in the year prior to screening;\n* Use of injectable or oral corticosteroids within one month prior to screening, or more than 3 bursts) within 6 months prior to screening;", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "AstraZeneca AstraZeneca", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "sanofi-aventis, US", "city": "Bridgewater", "state": "New Jersey", "zip": "08807", "country": "United States", "geoPoint": {"lat": 40.60079, "lon": -74.64815}}, {"facility": "Sanofi-Aventis Hungaria", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Sanofi-Aventis", "city": "Mexico", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "sanofi-aventis Poland", "city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "sanofi-aventis South Africa", "city": "Midrand", "country": "South Africa", "geoPoint": {"lat": -25.98953, "lon": 28.12843}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The number of subjects in section Participant Flow is related to the number of randomized subjects (= subject who were eligible for treatment period). This number is different to the number of subjects of the Intention to Treat (ITT) population in Outcome Measures. The statistical analyses of the Outcome Measures is related to the ITT population.", "recruitmentDetails": "Screening period 7-14 days, randomization with subsequent treatment period over 12 weeks", "groups": [{"id": "FG000", "title": "Placebo Metered Dose Inhaler (MDI)", "description": "Placebo MDI over twelve weeks (ITT population)"}, {"id": "FG001", "title": "Ciclesonide MDI 40 \u00b5g BID", "description": "Ciclesonide MDI 40 \u00b5g BID over twelve weeks (ITT population)"}, {"id": "FG002", "title": "Ciclesonide MDI 80 \u00b5g BID", "description": "Ciclesonide MDI 80 \u00b5g BID over twelve weeks (ITT population)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Number of randomized subjects is different to number of ITT population in Outcome Measures.", "numSubjects": "175"}, {"groupId": "FG001", "comment": "Number of randomized subjects is different to number of ITT population in Outcome Measures.", "numSubjects": "177"}, {"groupId": "FG002", "comment": "Number of randomized subjects is different to number of ITT population in Outcome Measures.", "numSubjects": "176"}]}, {"type": "Treatment Period", "achievements": [{"groupId": "FG000", "numSubjects": "172"}, {"groupId": "FG001", "numSubjects": "174"}, {"groupId": "FG002", "numSubjects": "175"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "ITT set = 163 patients", "numSubjects": "143"}, {"groupId": "FG001", "comment": "ITT set = 166 patients", "numSubjects": "155"}, {"groupId": "FG002", "comment": "ITT set = 172 patients", "numSubjects": "159"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "32"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "17"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Parent/legal guardian withdrawal", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo Metered Dose Inhaler (MDI)", "description": "Placebo MDI over twelve weeks (ITT population)"}, {"id": "BG001", "title": "Ciclesonide MDI 40 \u00b5g BID", "description": "Ciclesonide MDI 40 \u00b5g BID over twelve weeks (ITT population)"}, {"id": "BG002", "title": "Ciclesonide MDI 80 \u00b5g BID", "description": "Ciclesonide MDI 80 \u00b5g BID over twelve weeks (ITT population)"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "163"}, {"groupId": "BG001", "value": "166"}, {"groupId": "BG002", "value": "172"}, {"groupId": "BG003", "value": "501"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Aged 6 to <12 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "138"}, {"groupId": "BG002", "value": "145"}, {"groupId": "BG003", "value": "419"}]}]}, {"title": "Aged 4 to <6 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "27"}, {"groupId": "BG003", "value": "82"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "75"}, {"groupId": "BG003", "value": "204"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "104"}, {"groupId": "BG001", "value": "96"}, {"groupId": "BG002", "value": "97"}, {"groupId": "BG003", "value": "297"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12.", "description": "Change in FEV1 (Percent of predicted) from baseline to week 12. FEV1 was measured only in children between 6 to \\<12 years only. Least Squares Mean were adjusted for Baseline FEV1, age \\[yrs\\], pooled center, previous corticosteroid therapy and holding chamber.", "populationDescription": "Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement. The primary analysis was restricted to an age range between 6 and \\<12 years.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent of predicted FEV1", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo Metered Dose Inhaler (MDI)", "description": "Placebo MDI over twelve weeks (ITT population)"}, {"id": "OG001", "title": "Ciclesonide MDI 40 \u00b5g BID", "description": "Ciclesonide MDI 40 \u00b5g BID over twelve weeks (ITT population)"}, {"id": "OG002", "title": "Ciclesonide MDI 80 \u00b5g BID", "description": "Ciclesonide MDI 80 \u00b5g BID over twelve weeks (ITT population)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "138"}, {"groupId": "OG002", "value": "146"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.2", "spread": "1.06"}, {"groupId": "OG001", "value": "5.3", "spread": "1.06"}, {"groupId": "OG002", "value": "7.7", "spread": "1.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "groupDescription": "This is an analysis of the change from baseline to week 12 or last visit. In this pairwise comparison Ciclesonide was compared with Placebo by testing the average effect of Ciclesonide 40 and Ciclesonide 80 versus Placebo. As statistical test a t-test was used to compare the corresponding least-square means of both treatment groups.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.2696", "pValueComment": "Due to usage of a-priori ordered hypotheses, adjustment of p-values is not necessary. The pre-specified significance level was 0.05. The tests were carried out two-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model: Change in FEV1 = baseline FEV1 + age \\[yrs\\] + treatment + pooled center + previous corticosteroid therapy + holding chamber", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "This is an analysis of the change from baseline to week 12 or last visit. A t-test was used to compare the least-square means of Ciclesonide 80 versus Placebo.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0703", "pValueComment": "Due to usage of a-priori ordered hypotheses, adjustment of p-values is not necessary. The pre-specified significance level was 0.05. The tests were carried out two-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model: Change in FEV1 = baseline FEV1 + age \\[yrs\\] + treatment + pooled center + previous corticosteroid therapy + holding chamber", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "This is an analysis of the change from baseline to week 12 or last visit. As statistical test a t-test was used to compare the corresponding least-square means of Ciclesonide 40 versus Placebo.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9146", "pValueComment": "Due to usage of a-priori ordered hypotheses, adjustment of p-values is not necessary. The pre-specified significance level was 0.05. The tests were carried out two-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model: Change in FEV1 = baseline FEV1 + age \\[yrs\\] + treatment + pooled center + previous corticosteroid therapy + holding chamber", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Daily Asthma Symptom Score at Week 12.", "description": "Change in total daily asthma symptom score from baseline to week 12. 5-Point, ordinal scale specifying patient's experience of symptoms during day and night from 0 (no symptoms) to 4 (symptoms that prevent the patient from engaging in daily activities or sleep)", "populationDescription": "Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo Metered Dose Inhaler (MDI)", "description": "Placebo MDI over twelve weeks (ITT population)"}, {"id": "OG001", "title": "Ciclesonide MDI 40 \u00b5g BID", "description": "Ciclesonide MDI 40 \u00b5g BID over twelve weeks (ITT population)"}, {"id": "OG002", "title": "Ciclesonide MDI 80 \u00b5g BID", "description": "Ciclesonide MDI 80 \u00b5g BID over twelve weeks (ITT population)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}, {"groupId": "OG001", "value": "165"}, {"groupId": "OG002", "value": "170"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.96", "spread": "0.08"}, {"groupId": "OG001", "value": "-1.13", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.99", "spread": "0.08"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Use of Albuterol/Salbutamol at Week 12.", "description": "Change in albuterol/salbutamol use from baseline to week 12", "populationDescription": "Analyses are based on children of the ITT population. It includes all randomized patients who have a baseline and a valid post-randomization lung function measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Puffs per day", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo Metered Dose Inhaler (MDI)", "description": "Placebo MDI over twelve weeks (ITT population)"}, {"id": "OG001", "title": "Ciclesonide MDI 40 \u00b5g BID", "description": "Ciclesonide MDI 40 \u00b5g BID over twelve weeks (ITT population)"}, {"id": "OG002", "title": "Ciclesonide MDI 80 \u00b5g BID", "description": "Ciclesonide MDI 80 \u00b5g BID over twelve weeks (ITT population)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "166"}, {"groupId": "OG002", "value": "172"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.59", "spread": "0.08"}, {"groupId": "OG001", "value": "-0.87", "spread": "0.08"}, {"groupId": "OG002", "value": "-0.93", "spread": "0.08"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "The numbers of subjects at risk are based on the Safety Population. It was based on all randomized patients receiving at least one dose of the double-blind study medication after randomization.", "eventGroups": [{"id": "EG000", "title": "Placebo Metered Dose Inhaler (MDI)", "description": "Placebo MDI over twelve weeks (ITT population)", "seriousNumAffected": 1, "seriousNumAtRisk": 172, "otherNumAffected": 53, "otherNumAtRisk": 172}, {"id": "EG001", "title": "Ciclesonide MDI 40 \u00b5g BID", "description": "Ciclesonide MDI 40 \u00b5g BID over twelve weeks (ITT population)", "seriousNumAffected": 1, "seriousNumAtRisk": 174, "otherNumAffected": 38, "otherNumAtRisk": 174}, {"id": "EG002", "title": "Ciclesonide MDI 80 \u00b5g BID", "description": "Ciclesonide MDI 80 \u00b5g BID over twelve weeks (ITT population)", "seriousNumAffected": 4, "seriousNumAtRisk": 175, "otherNumAffected": 28, "otherNumAtRisk": 175}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 175}]}, {"term": "Forearm fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 175}]}, {"term": "Status asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 175}]}, {"term": "Electric shock", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 175}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 18, "numAffected": 12, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 9, "numAffected": 8, "numAtRisk": 175}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 18, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 10, "numAffected": 10, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 175}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 9, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 175}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 10, "numAffected": 10, "numAtRisk": 175}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 17, "numAtRisk": 172}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 174}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 175}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "AstraZeneca Clinical Study Information Center", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "1-877-240-9479"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Brazil"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000120481", "term": "Ciclesonide"}], "ancestors": [{"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M221371", "name": "Ciclesonide", "asFound": "Rigid", "relevance": "HIGH"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}